Two new tumor-specific antigenic peptides encoded by gene MAGE-C2 and presented to cytolytic T lymphocytes by HLA-A2

Int J Cancer. 2004 May 1;109(5):698-702. doi: 10.1002/ijc.20038.


We have identified 2 antigens recognized by several melanoma-specific cytolytic T lymphocyte clones isolated from a melanoma patient with a clinical history of tumor regression after immunotherapy. Both antigens are presented by HLA-A2 and encoded by gene MAGE-C2, a cancer-germline gene shown previously to be silent in normal somatic tissues and expressed in 40% of melanomas and in other tumor types. One antigen corresponds to peptide ALKDVEERV(336-344), whereas the other corresponds to peptide LLFGLALIEV(191-200). The CTL clones recognizing these 2 peptides also recognized allogeneic tumor cell lines expressing MAGE-C2 and HLA-A2. These 2 new peptides are the first known MAGE-C antigens and represent promising targets for cancer immunotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Amino Acid Sequence
  • Antigens, Neoplasm / genetics*
  • DNA, Complementary / metabolism
  • DNA, Neoplasm / metabolism
  • HLA-A2 Antigen / immunology*
  • Humans
  • Lymphatic Metastasis
  • Melanoma / genetics*
  • Melanoma / immunology*
  • Molecular Sequence Data
  • Neoplasm Proteins / genetics*
  • Reverse Transcriptase Polymerase Chain Reaction
  • T-Lymphocytes, Cytotoxic / immunology*


  • Antigens, Neoplasm
  • DNA, Complementary
  • DNA, Neoplasm
  • HLA-A2 Antigen
  • MAGEC2 protein, human
  • Neoplasm Proteins